Angion to Participate in Upcoming September Investment Conferences

Rhea-AI Summary

Angion Biomedica Corp (NASDAQ:ANGN) announced its management will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 AM EDT and participate in a fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 10:45 AM EDT. Webcasts for both events will be accessible on Angion's investor website and archived for 30 days. Angion is focused on developing novel therapies for acute organ injuries and fibrotic diseases, including ANG-3777 and ANG-3070.

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23^rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Details are as follows:

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13^th
Time: 7:00am Eastern US Daylight Time

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22^nd
Time: 10:45am Eastern US Daylight Time

Webcasts of the presentation and fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcasts of both events will remain archived on Angion’s website for approximately 30 days.

About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluated in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation and a Phase 2 trial in cardiac-surgery associated acute kidney injury. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

FAQ

When will Angion Biomedica present at the H.C. Wainwright conference?

Angion Biomedica will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM EDT.

What is the date and time for Angion's fireside chat with Oppenheimer?

The fireside chat with Oppenheimer will take place on September 22, 2021, at 10:45 AM EDT.

Where can I watch Angion's presentations online?

You can watch Angion's presentations online by visiting the events and presentations page under the investors section of Angion's website.

What is ANG-3777 being evaluated for?

ANG-3777 is being evaluated in a Phase 3 trial for delayed graft function in deceased donor kidney transplantation and in a Phase 2 trial for cardiac-surgery associated acute kidney injury.

What new trial is Angion starting for ANG-3070?

Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070 for the treatment of fibrotic disease in patients with primary proteinuric kidney diseases.